These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 38380373)

  • 1. Interferons in the treatment of myeloproliferative neoplasms.
    Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S
    Ther Adv Hematol; 2024; 15():20406207241229588. PubMed ID: 38380373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.
    How J; Hobbs G
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [No Abstract]   [Full Text] [Related]  

  • 5. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
    Okikiolu J; Woodley C; Cadman-Davies L; O'Sullivan J; Radia D; Garcia NC; Harrington P; Kordasti S; Asirvatham S; Sriskandarajah P; Saunders J; Saha C; Sanchez I; deLavallade H; McLornan DP; Harrison CN
    Leuk Res Rep; 2023; 19():100360. PubMed ID: 36590864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
    Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ropeginterferon alfa-2 b for the therapy of polycythemia vera].
    Červinek L
    Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
    Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
    [No Abstract]   [Full Text] [Related]  

  • 9. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.
    Hasselbalch H; Skov V; Kjær L; Larsen MK; Knudsen TA; Lucijanić M; Kusec R
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera.
    How J; Hobbs G
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1063-1068. PubMed ID: 36075385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon therapy for polycythemia vera].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(10):1290-1297. PubMed ID: 37914244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in the management of polycythemia vera and essential thrombocythemia.
    Bose P; Verstovsek S
    Ther Adv Hematol; 2019; 10():2040620719870052. PubMed ID: 31516686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
    El Bitar S; Arcasoy MO
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):80-89. PubMed ID: 38446475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy.
    Bang SY; Lee SE
    Hematol Rep; 2023 Mar; 15(1):172-179. PubMed ID: 36975731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Top advances of the year: Myeloproliferative neoplasms.
    Bhave RR; Mesa R; Grunwald MR
    Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.